MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder.
BACKGROUND
Previously, a biomarker panel was developed for use as an aid to major depressive disorder (MDD) diagnosis; it consisted of 9 biomarkers associated with the neurotrophic, metabolic, inflammatory, and hypothalamic-pituitary-adrenal axis pathways. This panel and associated algorithm produced good clinical sensitivity and specificity (92% and 81%, respectively) in differentiating MDD patients from individuals without MDD. To further validate the panel, we performed a prospective study using a larger set of new prospectively acquired MDD patients and a similarly collected population of nondepressed subjects. The addition of gender and body mass index (BMI) effects to the algorithm was also evaluated.


METHODS
Blood samples were obtained from MDD patients (n = 68) clinically evaluated at multiple sites in 2011 and 2012 using standard psychiatric assessment tools and structured clinical interviews according to DSM-IV criteria. Blood samples (n = 86) from nondepressed subjects were obtained as controls. MDD and nondepressed samples were randomized into independent training (n = 102) and validation sets (n = 52). Analytes in sera were quantified by immunoassay.


RESULTS
Training set biomarker data were used to develop a logistic regression model that included gender and BMI in a manner that allowed for their interaction with the biochemical analytes. For the training set, the sensitivity and specificity of the test (with 95% CI) were 93% (0.80-0.98) and 95% (0.85-0.99), respectively. This method (designated the MDDScore) was then applied to the independent validation set and had a sensitivity and specificity of 96% (0.77-0.98) and 86% (0.66-0.95), respectively. The overall accuracy for the training set was 94%; the validation set accuracy was 91%.


CONCLUSIONS
Examination of a randomized independent set of samples confirms the ability of the previously established biomarker panel to identify persons with MDD; the accuracy was over 90%. The improved model that adds gender and BMI to the previously established panel of 9 biomarkers is robust and simple; it provides the most rigorously tested, objective diagnostic test for MDD to date.
Ridge Diagnostics Inc, 2 Davis Dr, Research Triangle Park, NC 27709 jbilello@ridgedx.com.
John A
JA
Bilello
Linda M
LM
Thurmond
Katie M
KM
Smith
Bo
B
Pi
Robert
R
Rubin
Suzin M
SM
Wright
Floyd
F
Taub
Michael E
ME
Henry
Richard C
RC
Shelton
George I
GI
Papakostas
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood*; D002940:Circadian Rhythm / Q000502:physiology; D003865:Major Depressive Disorder / Q000097:blood* / Q000175:diagnosis* / Q000523:psychology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012016:Reference Values; D055815:Young Adult
D015415:Biomarkers; D006854:Hydrocortisone